Abiopharma

🔍 Civik Thomas (Executive)

Company: Pyxis Oncology, Inc. (PYXS)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 250,956 shares of Stock Option (Right to Buy) at $1.49 per share (Derivative)
  Date: 2026-08-12 | Code: A | Expires: 2036-02-03 | Exercise: 2026-08-12 | equity_swap_involved: false | shares_owned_after: 941,087.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents the performance-based portion of an option that was granted on February 3, 2026, which shares subject to this portion of the option were to become vested in full upon the completion of a successful financing transaction or a successful strategic transaction during the reporting person's continued service as Interim Chief Executive Officer or within six months thereafter. The performance conditions were deemed to have been met on August 12, 2026, as determined by the Board.